Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults

13. marts 2013 opdateret af: Sinovac Biotech Co., Ltd

A Blinded, Randomized and Controlled Clinical Trial of An Inactivated Enterovirus Type 71 Vaccine in Healthy Adults

A blind, randomized and placebo-controlled clinical trial with Inactivated Enterovirus Type 71 Vaccines in healthy adults

Studieoversigt

Detaljeret beskrivelse

A total of 36 eligible subjects aged from 18 to 49 years will be enrolled in the study, they will be randomized to receive two different dosage of vaccine candidate or placebo to evaluate the safety of this vaccine in adults

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

36

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Guangxi
      • Nanning, Guangxi, Kina
        • GuangXi Center for Diseases Control and Prevention

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 49 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Healthy males and females, aged from 18 to 49 years old. Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
  2. Provided legal identification for the sake of recruitment.
  3. Subjects are able to understand and sign informed consents.

Exclusion Criteria:

  1. Histroy of Hand-foot-mouth Disease
  2. Women of lactation, pregnancy or about to be pregnant in 60 days
  3. Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
  4. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
  5. Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
  6. Epilepsy, seizures or convulsions history, or family history of mental illness
  7. Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
  8. History of asthma, angioedema, diabetes or malignancy
  9. History of thyroidectomy or thyroid disease that required medication within the past 12 months
  10. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  11. Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
  12. Acute illness or acute exacerbation of chronic disease within the past 7 days
  13. Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
  14. History of any blood products within 3 months
  15. Administration of any live attenuated vaccine within 28 days
  16. Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
  17. Axillary temperature > 37.0 centigrade before vaccination
  18. Abnormal laboratory parameters before vaccination
  19. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Group 1: 200U EV71 vaccine
12 adults received 3 doses of 200U EV71 vaccine 14 days apart
A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
Andre navne:
  • EV71 Vaccine
Eksperimentel: Group 2: 400U EV71 vaccine
12 adults received 3 doses of 400U EV71 vaccine 14 days apart
A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
Andre navne:
  • EV71 Vaccine
Placebo komparator: Group 1: Placebo
6 adults received 3 doses of placebo 14 days apart
Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
Andre navne:
  • EV71 Vaccine
Placebo komparator: Group 2: Placebo
6 adults received 3 doses of placebo 14 days apart
Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
Andre navne:
  • EV71 Vaccine

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
To evaluate the safety and tolerability of the inactivated Enterovirus Type 71 Vaccine in adults by different doses
Tidsramme: 3 months
3 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Yan-ping Li, MD, Guangxi Centers for Disease Control and Prevention

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. december 2010

Primær færdiggørelse (Faktiske)

1. februar 2011

Studieafslutning (Faktiske)

1. februar 2011

Datoer for studieregistrering

Først indsendt

7. januar 2011

Først indsendt, der opfyldte QC-kriterier

7. januar 2011

Først opslået (Skøn)

10. januar 2011

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

15. marts 2013

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. marts 2013

Sidst verificeret

1. marts 2013

Mere information

Begreber relateret til denne undersøgelse

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Infektion; Viral, enterovirus

Kliniske forsøg med Inactivated Enterovirus Type 71 Vaccine

Abonner